Thermo Fisher Scientific (TMO) Price Target Raised to $227.00 at Morgan Stanley

Thermo Fisher Scientific (NYSE:TMO) had its target price raised by research analysts at Morgan Stanley from $223.00 to $227.00 in a report released on Thursday. The firm currently has an “overweight” rating on the medical research company’s stock. Morgan Stanley’s target price suggests a potential upside of 2.09% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. Barclays raised their price objective on Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a report on Thursday. Leerink Swann restated an “outperform” rating and issued a $239.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Thursday. They noted that the move was a valuation call. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price objective for the company in a report on Tuesday, October 31st. BTIG Research assumed coverage on Thermo Fisher Scientific in a report on Friday, January 5th. They issued a “buy” rating and a $230.00 price objective for the company. Finally, Evercore ISI assumed coverage on Thermo Fisher Scientific in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 price objective for the company. Two research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $220.50.

Shares of Thermo Fisher Scientific (TMO) traded down $1.75 during midday trading on Thursday, hitting $222.36. The stock had a trading volume of 1,897,309 shares, compared to its average volume of 1,606,986. The company has a market cap of $89,400.00, a PE ratio of 39.71, a price-to-earnings-growth ratio of 1.74 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. Thermo Fisher Scientific has a 12 month low of $150.23 and a 12 month high of $226.44.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.66 by $0.13. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. Thermo Fisher Scientific’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.41 EPS. sell-side analysts anticipate that Thermo Fisher Scientific will post 9.36 earnings per share for the current fiscal year.

In related news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the sale, the chief executive officer now directly owns 252,577 shares in the company, valued at approximately $47,582,981.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.49% of the company’s stock.

A number of large investors have recently modified their holdings of TMO. Bank of Nova Scotia Trust Co. acquired a new stake in Thermo Fisher Scientific during the third quarter worth approximately $106,000. Ropes Wealth Advisors LLC lifted its position in Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after acquiring an additional 97 shares during the last quarter. Atlantic Trust LLC acquired a new stake in Thermo Fisher Scientific during the second quarter worth approximately $138,000. Acrospire Investment Management LLC lifted its position in Thermo Fisher Scientific by 66.7% during the second quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock worth $174,000 after acquiring an additional 400 shares during the last quarter. Finally, Glassman Wealth Services lifted its position in Thermo Fisher Scientific by 23.1% during the second quarter. Glassman Wealth Services now owns 1,039 shares of the medical research company’s stock worth $181,000 after acquiring an additional 195 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was published by American Banking and Market News and is the property of of American Banking and Market News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/02/01/thermo-fisher-scientific-tmo-price-target-raised-to-227-00-at-morgan-stanley.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)